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Background: Several environmental and genetic factors are associated with high levels of lipids in obese patients.
Apolipoprotein B (ApoB) is the major protein component of low-density lipoproteins (LDL), very-low density lipoproteins
(VLDL) and chylomicrons and plays a central role in lipid metabolism. Several apoB restriction fragment length
polymorphisms (XbaI, EcoRI, MspI) have been reported to be associated with variation in lipid levels and obesity.
To date, no data are available on the relationship between XbaI polymorphism and lipid levels in Egyptian populations.
Following clinical profiling, 178 obese (body mass index [BMI] >25 kg/m2) and 178 age-matched non-obese (BMI≤
25 kg/m2) subjects were included in this case–control study. All samples were analysed for total cholesterol,
triglycerides and HDL-cholesterol. Genetic analysis of apoB XbaI (X) was performed using Polymerase Chain
Reaction-Restriction Fragment Length polymorphism (PCR-RFLP). The aim of this study was to assess the association
of apoB XbaI gene polymorphism (X) and lipid profiles in obese and non-obese Egyptian populations.
Results: Obese subjects demonstrated significantly higher values of waist-to-hip ratio, blood pressure, and total lipid.
However, in our sample we did not find significant differences in apoB XbaI gene polymorphism (X) genotype or allele
frequencies. Moreover, none of the studied lipid parameters showed any association with the gene polymorphism.
Conclusion: This study reveals no significant association of apoB XbaI gene polymorphism (X) with obesity or lipid
profiles in an Egyptian population.Introduction
Obesity is a common, preventable and often underesti-
mated, condition of clinical and public health import-
ance in many countries. In many societies, including
Egypt, obesity has been viewed as a sign of wellbeing or
high social status. This has effectively led to the denial,
by (generally high status) health care professionals and
the public, that obesity is a disease. This has contributed
to improper identification and management of obesity
and the lack of effective public health strategies to com-
bat its rise to epidemic proportions in all age groups [1].
“The most shocking thing is the degree to which obesity is
now affecting developing as well as developed economies”,
says Tim Lobstein of the International Association for* Correspondence: afawzy1978@yahoo.com
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unless otherwise stated.the Study of Obesity in London. “The problems caused
by over consumption of fats and sugars are now global, not
just Western, problems”. The World Health Organization
(WHO) reported that worldwide obesity has nearly dou-
bled since 1980. The increasing prevalence of obesity
places a large burden on health care use and costs. In
2006, WHO predicted that obesity in the developing
world would overtake that in rich countries by 2010.
The situation in Egypt confirms the WHO prediction.
Nearly 70% of the adult population – about 56.5 million
people – are overweight, according to a new study pub-
lished in The Lancet [2]. According to the study, Egypt
ranks 7th in the World for obesity.
Obesity is associated with a greater risk of disability or
premature death due to type 2 diabetes mellitus, cardio-
vascular diseases (such as stroke and coronary heart dis-
ease), gall bladder disease, certain cancers (endometrial,
breast, prostate, colon) and non-fatal diseases including
gout, respiratory conditions, gastro-esophageal refluxThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ries serious implications for psychosocial health, mainly
due to an evolving societal prejudice against fatness.
It has been reported that polymorphisms in genes con-
trolling appetite and metabolism are associated with sus-
ceptibility to obesity (when sufficient food is available).
More than 41 such genes and many variations in theses
genes have been shown to be linked to the development
of obesity when the environment is permissive [4]. How-
ever, genetics is but part of a complex, involving societal,
environmental and individual psychological factors.
In Man insoluble lipids are transported in blood as
lipoprotein complexes with one or more apolipoproteins.
Low-density lipoprotein (LDL) is 75% lipid (cholesterol
and cholesteryl esters) and 25% protein. A high level of
LDL is a risk factor for cardiovascular disease [5]. Apoli-
poproteinB (ApoB) plays a central role in lipid metabol-
ism as the main protein component of VLDL and LDL.
It also serves as the ligand for removal of LDL from the
circulation by LDL-receptor-mediated endocytosis [6].
ApoB is the protein primarily responsible for transport-
ing cholesterol in LDL to tissues. Although it is uncer-
tain what functional role ApoB plays in LDL, it is
absolutely required for its formation. ApoB on the LDL
particle acts as a ligand for LDL receptors in various cells
throughout the body. High plasma ApoB levels are a fac-
tor contributing to plaques that cause atherosclerosis [7].
Variants of the apoB gene may therefore be involved in
the pathogenesis of obesity.
The gene coding for human ApoB [ID: 338] is 43 kb
in length, located on the short arm of Chromosome 2
(2p23-p24) [8]. Several single nucleotide polymorphisms
in the apoB gene have been associated with variation in
lipid levels and obesity. These include XbaI (X; 9), EcoRI
(R; 10) and MspI (M; 11). A single nucleotide transition
(C#T) at position 7673 creates a restriction site (ACC→
ACT) for XbaI enzyme characterizing the ‘X+’ allele,
whereas no change determines the ‘X-‘ allele. The changed
amino acid at codon 2488 of exon 26 is silent, Thr2488Thr
(T2488T)’ [7]. This polymorphism has been found to be
associated with inter-individual variability of lipid levels,
but the results are inconsistent [9]. Epidemiological studies
have shown an association between apoB gene polymor-
phisms and generalized and regional obesity and an in-
crease in various lipoprotein subfractions (total cholesterol
[TC], low density lipoprotein cholesterol [LDL-C], trigly-
ceride [TG]), and atherosclerosis [10-12]. Most of these
studies have been carried out in Caucasian populations. It
has been reported that the X+ allele of the Apo B gene is a
risk factor for the development of cholelithiasis (gallstones)
in Chinese patients [13]. However, in a Mexican popula-
tion study no association was shown to exist between the
apoB XbaI polymorphism and cholelithiasis [14]. A signifi-
cant association of apoB XbaI gene polymorphism withobesity and serum lipid levels [12] has been documented,
but contradictory results are also available. Misra et al.
[15] reported that apoB XbaI gene polymorphism did not
associate with obesity.
In this study we have attempted to correlate apoB XbaI
gene polymorphisms with obesity and lipid profile in obese
and non-obese Egyptian subjects.
Subjects and methods
Subjects
178 obese individuals aged 19 to 60 years were recruited
in Egypt. 178 normal Egyptian individuals with no diagno-
sis of obesity, and no family history of obesity were also
recruited. The enrolled subjects were referred to the Na-
tional Research Center clinic during the period 2012 –
2013. Their ages and sex were matched with the obese
group. All subjects gave their informed consent and the
protocol was approved by the National Research Center of
Egypt.
All subjects gave detailed clinical histories, and mea-
surements included: height, weight, BMI, and waist-to-hip
ratio (WHR). BMI was calculated as weight in kilograms
divided by the square of height in metres and obesity was
defined as BMI ≥ 25 kg/m2. Only non-smoking, normo-
tensive (systolic < 130 mmHg; diastolic < 85 mmHg) and
non-diabetic (fasting blood sugar < 110 mg/dl) subjects
were included. Subjects were considered as normal if they
fall in normal ranges for various parameters. For example,
leptin = 2–11 mg/ml, serum insulin = 0–30 μU/ml. A his-
tory of coronary artery disease, neoplasia, congenital and
mental disorders, and endocrine disorders such as myxoe-
dema and Cushing syndrome were defined as additional
criteria for exclusion from this study.
Anthropometry measurements
Body weight was measured to the nearest 0.1 kg, and
height was measured to the nearest 0.01 m [16]. The waist
circumference was measured half way between the lower
rib and iliac crest, the hip circumference was measured
over the widest part in the gluteal region, and the WHR
was calculated [17].
Sample collection
Blood (10 ml) was collected without anticoagulant after a
12-h fast and the serum was used for the determination of
lipids from all subjects. The collected blood for serum
preparation was kept in an upright position at room
temperature for 30 minutes to allow collecting. Centrifu-
gation for 15 min 2000 RCF with no braking followed.
The supernatant (serum) was carefully aspirated at room
temperature and transferred into tubes. Unturbid samples
were aliquoted into cryovials and stored at – 80°C for sub-
sequent analysis. Blood was collected in vacutainer tubes
Table 1 Obesity and lipid parameters in the Egyptian
cohort
Parameter Obese (n = 178) Non-obese
(control; n = 178)
p-value
WHR 0.95 ± 0.03 0.82 ± 0.04 <0.001
SBP (mmHg) 123.89 ± 11.91 116.18 ± 9.25 0.001
DBP (mmHg) 81.82 ± 8.85 78.27 ± 7.84 0.002
TC (mg/dl) 264.52 ± 29.78 169.84 ± 31.23 <0.001
HDL-C (mg/dl) 31.48 ± 1.56 41.68 ± 4.78 <0.001
VLDL-C (mg/dl) 30.86 ± 10.43 20.86 ± 4.13 <0.001
TG (mg/dl) 197.35 ± 21.56 103.76 ± 14.87 <0.001
LDL-C (mg/dl) 175.12 ± 36.75 106.64 ± 34.96 <0.001
WHR: Waist-to-hip ratio; SBP: Systolic blood pressure; DBP: Diastolic blood
pressure; TC: Total cholesterol; HDL-C: High density lipoprotein cholesterol;
LDL-C: Low density lipoprotein cholesterol; VLDL-C: Very low density
lipoprotein cholesterol; TG: Triglyceride.
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tracted from peripheral blood leukocytes [18].
Biochemical parameters investigations
Five lipid parameters (Total Cholesterol, Triglycerides,
High Density Lipoprotein, Low Density Lipoprotein, and
Very Low Density Lipoprotein) were measured in obese
and non-obese subjects. TC and TG were measured by
enzymatic colorimetric tests [19,20]. HDL-cholesterol
concentrations were determined by enzymatic assay after
phosphotungstic acid and magnesium precipitation [21].
LDL-cholesterol was calculated according to Friedewald’s
formula and VLDL-cholesterol was calculated using the
formula TG/5 [22]. Fasting blood sugar was assayed by
glucose oxidase-peroxidase) method [23]. All values were
measured in mg/dl. Serum leptin and insulin was assayed
to exclude monogenic obesity. In addition, estimation of
FT3, FT4, TSH, growth hormone, FSH and LH was done
to exclude endocrine causes.
DNA isolation and genotyping
Genomic DNA extraction was done using salting out
methodology [18]. The isolated DNA was of good quality
(absorbance 260 nm/280 nm, ratio > 1.75). The desired
segment was amplified by PCR using the apoB XbaI
protocol [23] with the respective primers (Fermantas Inc.,
USA): 5′- GGAGAC TATTCAGAAGCTAA-3′ as for-
ward primer and 5′-GAAGAGCC TGAAGACTGACT-3′
as reverse primer. The amplified products were restriction
digested using XbaI and digested products were electro-
phorized on 1.5% agarose gel containing ethidium bromide
(1%). After the run was completed, the gel was visualized
under UV light. The genotypes for all samples were reas-
sessed twice to confirm the results and ensure reproducibil-
ity. Some uncertain genotypes were validated by purifying
the PCR products using GeneJET gel extraction and DNA
cleanup kit (Thermo Fisher Scientific Inc. USA) and were
directly sequenced on ABI Prism 310 Automated Sequencer,
using the ABI Prism Big Dye Terminator Cycle Sequencing
Ready Reaction Kit (PE Applied Biosystems).
apoB gene XbaI polymorphism status
The following nomenclature has been used to specify the
genotypes at apoB XbaI: X-/X- (wild-type (CC) or homozy-
gous absence of restriction site), X-/X+ ((CT) heterozygous
absence of restriction site deletion); and X+/X+: (rare-type
(TT) or homozygous presence of restriction site).
Statistical analysis
All the statistical calculations for biochemical factors
were performed using IBM SPSS Statistics v. 11.5 for
Windows. For each variable, the values were expressed
as mean ± SD. Data was evaluated by t test and one-way
analysis of variance. Allele and genotypic frequencies forapoB XbaI was calculated with the gene counting
method. Hardy-Weinberg equilibrium, as well as com-
parison of the categorical data i.e., different apoB geno-
types among non-obese controls and obese subjects
were made by the χ2 test. Odd’s ratios were calculated
with a 95% confidence interval limit using 2 × 2 contin-
gency table and p-value < 0.05 was used as the level of
significance.
Result
356 subjects comprising obese (84 male and 94 female)
and non-obese (91 male and 87 female) adults were evalu-
ated. The mean BMI ( kg/m2) of the obese and non-obese
subjects was 29.91 ± 3.56 and 20.37 ± 2.54, respectively.
The WHR (p-value < 0.001), Systolic (p-value < 0.001) and
diastolic (p-value < 0.002) blood pressures, though in nor-
mal range, were significantly higher in obese subjects as
compared to non-obese subjects. Fasting blood glucose
(mg/dl) was significantly higher in obese subjects as com-
pared to non-obese subjects. TC, TG, LDL, and VLDL
were also higher (p-value ≤ 0.001) in obese subjects as
compared to non-obese subjects. On the contrary, HDL
was significantly higher (p-value < 0.001) in non-obese as
compared to obese subjects Table 1.
Association of apoB XbaI gene polymorphism (X) with
obesity
Initial genotype analysis indicated the presence of the
XbaI polymorphism (X) in the Egyptian population and
this was confirmed by direct sequencing. The genotype
frequencies did not deviate significantly from the Hardy-
Weinberg expectations in the obese (χ2 = 0.09, p = 0.77)
and non-obese control subjects (χ2 = 0.025, p = 0.47).
Analysis did not reveal a positive association between
the apoB XbaI gene polymorphism (X) and obesity-
related phenotypes. The observed allele frequencies were
X− (C), 70.2% versus 67.1%; and X+ (T), 32.3% versus
Table 2 apoB XbaI Polymorphism analysis (X-/X- (CC), X-/X+ (CT), X+/X+ (TT) and X- (C) and X+ (T) alleles) in obese
subjects (n = 178) and non-obese controls (n = 178)
apoB genotype apoB allele
CC CT TT C T
Non-obese (%) 88 63 27 151 117
(49.4) (35.4) (15.2) (67.1) (32.9)
Obese (%) 97 56 25 250 115
(54.5) (31.5) (14) (70.2) (32.3)
p-value - 0.200 0.427 - 0.250
OR 1.0 0.768 0.746 1.0 0.727
(95% CL) (reference) (0.456 – 1.23) (0.374 – 1.64) (reference) (0.538 – 1.276)
OR = Odd ratio; 95% CI = confidence interval at 95%.
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of X + X+ (TT) genotype did not differ significantly in
obese and non-obese subjects. Similarly, frequency of
X+ (T) allele was not significantly different in the two
groups Table 2. In obese and in non-obese subjects,
none of the obesity related parameters (especially TC,
TG, LDL, HDL, and VLDL) were associated with geno-
types of apoB Table 3. The apoB X+ allele did not
show any statistically significant difference with clinic-
ally profiled obese or non-obese subjects Table 3. Lipid
levels (TC, TG, LDL, HDL, and VLDL) were signifi-
cantly different in obese and non-obese subjects. No
significant association was demonstrated between geno-
types of apoB XbaI gene polymorphism (X+ carrier and
X+ non-carrier) and lipid profile in obese and non-obese
subjects Table 3.Table 3 Association of apoB XbaI gene polymorphism (X) with
Parameter TC (mg/dl) HDL-C (mg/dl)
Obese subjects
X-/X- (CC) 253.50 ± 5.67 32.12 ± 3.54
X-/X+ (CT) 245.38 ± 8.91 31.48 ± 2.58
X+/X+ (TT) 253.3 ± 4.15 31.38 ± 2.11
P value 0.973 0.412
X+ carrier 273.86 ± 5.85 32.51 ± 4.26
X+ non-carrier 273.54 ± 4.82 31.83 ± 3.68
P value 0.428 0.841
Non-obese subjects
X-/X- (CC) 172.78 ± 9.73 43.24 ± 5.93
X-/X+ (CT) 176.75 ± 6.15 42.83 ± 5.47
X+/X+ (TT) 171.53 ± 4.38 42.03 ± 5.12
P value 0.872 0.752
X+ carrier 219.89 ± 4.69 38.94 ± 3.59
X+ non-carrier 206.18 ± 6.72 41.30 ± 2.31
P value 0.062 0.074
TC: Total cholesterol; HDL-C: High density lipoprotein cholesterol; LDL-C: Low densit
TG: Triglyceride.Discussion
We have examined the genotypic and allelic frequencies
and the effect of apoB XbaI polymorphism (X) on obes-
ity and lipid profile in well-defined Egyptian obese and
non-obese populations. The apoB XbaI polymorphism
(X) was selected for the present study by virtue of its
documented association with obesity and dyslipidemia
elsewhere [12]. Various studies have shown an associ-
ation between the Apo B gene polymorphisms with lipo-
protein subfractions (TC, LDL-C, and TG) [21-23].
However, here we showed that there was no significant
difference in the genotype and allele frequencies of apoB
XbaI polymorphism between obese and non-obese sub-
jects. Saha et al. [14] also reported no significant differ-
ence in allelic frequencies of XbaI gene polymorphism of
the apoB gene. In addition, another study did not showobesity related parameters
HDL-C (mg/dl) TG (mg/dl) TG (mg/dl)
27.74 ± 5.34 179.75 ± 8.34 178.13 ± 6.75
29.74 ± 2.41 178.51 ± 3.42 175.24 ± 5.67
32.53 ± 1.31 181.32 ± 3.58 169.36 ± .32
0.736 0.231 0.872
28.98 ± 3.57 147.64 ± 3.82 212.45 ± 6.67
28.57 ± 1.94 146.56 ± 4.85 211.95 ± 4.74
0.263 0.471 0.581
21.00 ± 3.35 104.6 ± 6.59 104.35 ± 6.69
19.63 ± 3.14 98.14 ± 5.67 105.94 ± 6.51
21.25 ± 2.89 106.56 ± 4.38 107.13 ± 4.87
0.234 0.213 0.842
25.57 ± 2.73 123.54 ± 3.35 155.51 ± 4.42
23.93 ± 3.74 115.85 ± 6.78 146.16 ± 9.79
0.323 0.32 0.061
y lipoprotein cholesterol; VLDL-C: Very low density lipoprotein cholesterol;
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ism with obesity and lipid profile in north Indians [24].
In the present study, a comparison of clinical variables
was also done in relation to the genotypes of the apoB
XbaI gene in obese and non-obese subjects but no asso-
ciation was found with serum lipid levels. Our results
were in agreement with a previous study, [25] while
Saha et al. [19] reported no association between the apoB
XbaI gene and serum lipids levels.
It may be that apoB XbaI polymorphism exhibits
population specific variation, which may be due to gene
and environment interactions. apoB XbaI polymorphism
does not lead to changes in the amino acid sequence and
cannot be implicated at structure level. It is possible that
some other polymorphism in its vicinity might be present,
which is in linkage disequilibrium with apoB XbaI poly-
morphism and accountable for the observed association
with obesity and lipid levels in other studies. The effect of
apoB XbaI polymorphism on the lipid levels is due to link-
age disequilibrium with ins/del polymorphism, which
causes an amino acid change in the signal peptide of the
apoB gene. Saha et al. [11] showed a strong disequilibrium
between ins/del polymorphism and the XbaI polymorph-
ism of apoB gene. Among Tunisian population the XbaI
polymorphism effect was only observed for triglyceride in
men. This rare study indicated an influence of XbaI poly-
morphism of Apo B gene on serum total-cholesterol,
triglycerides and apolipoprotein A1 concentrations [26].
Moreover, gene–environment interaction may also re-
sponsible for the inconsistency of data due to differences
in the diet and lifestyle of populations of various part of
the world. It has been reported that overweight subjects
from the Bichat Hospital in Paris with the Del allele of the
apo B signal peptide polymorphism were more susceptible
to high LDL cholesterol levels but their LDL cholesterol
responds well to diet. This study shed light about the im-
portance of the interaction between genes and nutritional
environment in the determination of the lipid levels [27].Conclusion
In summary, there was no evidence of association of
apoB polymorphisms (XbaI) with obesity and serum
lipid levels in the studied Egytian cohorts. There may be
several reasons for the differences observed in the vari-
ous studies. The populations studied in different studies
may have been genetically different. In view of the strong
associations reported in some studies, we suggest larger
sample sizes involving differing ethnicities may be
needed to study the association of XbaI polymorphism
with obesity [9,10,18].Competing interests
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